|Chairman of the Board
Representative Executive Officer, Executive Chairman
|Shinichi founded Sosei in June 1990 as a technology transfer company, having built up a wealth of experience during his years in the industry. He graduated from Tokyo University with an M.S. in Biochemistry and a major in Cultural Anthropology, going on to work in various positions in Planning and Development at Fujisawa Pharmaceutical Co. Ltd.
Shinichi was later appointed Representative Director (CEO) of Genentech Limited (Genentech Inc's Japan subsidiary). He has advised various companies including Genentech, GenPharm, Geron, IDEC, Pharmacyclics, and Vernalis, and played an important role in completing several significant deals.
Representative Executive Officer, CEO
|Peter has more than two decades of experience in the pharmaceutical industry encompassing strategic and operational leadership expertise across global geographies, functions and business segments. He had a 23-year career at GlaxoSmithKline, where he held multiple senior roles including General Manager of China, Head of Global Marketing and Senior VP of International Commercial Operations. From 2009, he has been a consultant specialising in supporting strategic growth opportunities in small- and medium-sized innovation-based life science companies; Syngene, a subsidiary of Biocon, Asia's largest biotechnology company; and Kromek Ltd, an AIM-listed company. He is also Non-executive Chairman of Fermenta Biotech Ltd, a subsidiary of DIL, a Mumbai-listed company. Peter completed his B.Sc Combined Honours in Physiology/ Zoology from Sheffield University.|
|Takuya earned his MBA at the University of Pennsylvania Wharton School after graduating from the Faculty of Economics at The University of Tokyo in June 2005. During his distinguished thirty years with the Bank of Japan, he held various positions including Chief Cashier and General Secretariat of Policy Board. In 1998, Takuya was made President and CEO of Nippon Credit Bank by prime ministerial appointment. He spent three years overseeing the nationalization of the bank and its subsequent transition to private ownership. Since 2005, Takuya has provided expertise on regulatory and compliance matters as Chief Executive Officer and President of Promontory Financial Group Global Services Japan, LLC. Takuya has been a Director of Sosei Group Corporation since June 2005.|
|Declan received his Medical degree from Glasgow University in 1975 and joined Pfizer in 1982, where he was in charge of the sertraline® (Zoloft) clinical development programme. He has held a number of senior positions in research and development in Pfizer in the United States, United Kingdom, and Japan. He retired from Pfizer in 2007 as the Head of Worldwide Development. Declan has since held the positions of Interim CEO and Chief Medical Officer of Amarin Corporation. He is Executive Chairman of Biohaven Pharmaceuticals, CEO of Portage Biotech and co-founder and managing partner of Topix.
Declan is on the Board of the not-for-profit Pulmonary Vascular Research Institute. He has held Visiting Professorships at Harvard School of Public Health, Glasgow University Medical School, and Kitasato University (Tokyo) and is Adjunct Professor of Psychiatry at the University of Cork. He is a Fellow of the Royal College of Physicians and the Faculty of Pharmaceutical Medicine in the United Kingdom and received a Doctorate of Science from the University of Kent, UK.
|Tomohiro is a partner at TMI Associates, which he co-founded in October 1990.
Tomohiro entered the Legal Training and Research Institute, Supreme Court of Japan in April 1978 and registered with Dai-ichi Tokyo Bar Association in April 1980. He joined Nishimura and Sanada Law Office in April 1980, becoming a partner in August 1985. He has also held positions at law firms Mason & Sloane, LLP. USA., Pollock, Bloom & Dekom, USA, and Pryor, Cashman, Sherman & Flynn, USA.
Tomohiro has been Outside Director of Nippon Shikizai, Inc. since November 1999, Outside Statutory Auditor of WOWOW INC. since June 2016, and Outside Director of Trust Capital Co., Ltd. since May 2016. He joined the External Board of Sosei Group Corporation in 2010.
|Chairman of the Board
Representative Executive Officer, Chief Executive Chairman
Representative Executive Officer, CEO
|Executive Vice President, Chief R&D Officer|
|Former Visiting Professor of Biochemistry at Imperial College, London
Former Head of the Molecular Sciences Division of Glaxo Wellcome Inc. (present Glaxo Smithkline plc.)
Former CEO of Inpharmatica Ltd.（present Galapagos NV)
Founder and CEO of Heptares Therapeutics Ltd.
|Executive Vice President, CSO|
|Fiona has a BSc in biochemistry from Bath University and a PhD in neuroscience from Cambridge University. She has more than 20 years' experience in drug discovery with particular expertise on GPCRs. She led the first group to show that GPCRs could form heterodimers and has published more than 60 peer-reviewed papers in the area of GPCRs. She spent 12 years at GlaxoWellcome/GlaxoSmithKline where she held a number of senior positions including Head of the Department of Molecular Pharmacology and Head of GPCR research. She was Director of Discovery Pharmacology, Europe for Millennium Pharmaceuticals and then spent several years as an independent consultant to a variety of venture capital and biotech companies, including Inpharmatica, Merlion, Galapagos, Paradigm, Cancer Research Technology, Shire, CellAura, Bioimage, Chroma, Ablynx and Sentinel. She was chair of the BBSRC biochemistry and cell biology committee for three years and is currently Chair of the CRUK Drug Discovery Committee and Vice-chair of the Wellcome Trust Seeding Drug Discovery Committee. Fiona received the Malcolm Campbell Memorial Prize 2015, awarded by the UK Royal Society of Chemistry's Biological and Medicinal Chemistry Sector, in recognition of her contribution to GPCR drug discovery.|